Dr. Bill Colston was previously the CEO and scientific founder of QuantaLife Inc.™, a successful biotechnology startup company. QuantaLife developed the most accurate genetic analysis system in the world, now sold internationally (droplet digital PCR™). Dr. Colston raised multiple rounds of private funding, moving from concept to manufactured product in a fraction of the time of comparable companies in this space. QuantaLife grew exponentially during his tenure, from the four scientific founders during the inception in 2008 to over sixty employees by the time it was sold to BioRad in 2011. Prior to QuantaLife, Dr. Colston worked within the University of California (UC) National Labs for almost 20 years, ultimately serving in multiple different senior leadership roles. A prolific scientific writer and inventor, he has authored numerous publications and patents. Dr. Colston received his BS in biology from the University of Texas, Austin, in 1989 and his Ph.D. in biomedical engineering from the University of California, Davis, in 1997.
Ted has 20 years of experience in the biotechnology industry establishing and directing innovative research as well as developing and commercializing technologies and products. At HealthTell, Ted is responsible for establishing development strategies and performance specifications, developing robust technology platforms, and executing regulatory compliant development of new HealthTell products as well as introduction of these products into commercial laboratory settings. Prior to joining HealthTell, Ted held senior management positions at Tethys Bioscience, a diagnostic company focused on discovering, developing and commercializing multianalyte tests for cardiometabolic disease risk stratification. Most recently at Tethys, Ted was Senior Vice President responsible for all R&D and product development efforts. Prior to Tethys, Ted was Director of the Biosecurity and Nanosciences Laboratory at Lawrence Livermore National Laboratory, a 60 person R&D organization focused on translating basic science discoveries and capabilities into advances for biosecurity. Ted was also a founder and Chief Scientific Officer at Invenux Incorporated, a drug discovery and development company and held research and development positions at NeXstar Pharmaceuticals and Replidyne. Ted received his B.S. in Chemistry from California Polytechnic State University, Summa Cum Laude, and his PhD in Organic Chemistry from The Scripps Research Institute.
Dr. David Smith has more than 15 years commercialization and operations experience in the life science industry in both startup and established companies including Complete Genomics, Codon Devices, Roche/454 Life Sciences, and Affymetrix. With a focus on process development, product development, and operational scale up, David has a demonstrated capability in transforming technology from feasibility to commercial readiness and sustainable growth. David received his BS in chemistry from the North Central College in Naperville, and his Ph.D. in chemistry from the University of Arizona in Tucson, AZ..
Dr. Sykes brings to HealthTell more than 20 years of experience inventing and developing innovative molecular and chemical technologies to manipulate the immune system toward better health. As a Research Professor in Medicine at the University of Texas, Southwestern Medical Center, she developed new recombinant-DNA technologies and vaccine discovery approaches. These technologies were used as the basis for launching her first biotechnology company in 2001, Eliance, subsequently acquired by MacroGenics. As Director of Research at Macrogenics, Inc. she implemented the high-throughput, synthetic methods for genetic engineering and the empirical, yet combinatorial approach to antigen discovery. Her team of ~20 scientists identified lists of protective antigens for a number of biothreat and commercially relevant pathogens.
In 2005 she was recruited to a new translational-research center, The Biodesign Institute at Arizona State University, as an Assistant Professor in the School of Life Sciences. She grew a multi-disciplinary, highly collaborative team that explored innovative molecular and immunological technologies to enable the development of better vaccines against both infectious and chronic diseases. While these innovations were initially centered on vaccine discovery, Dr. Sykes’ team has since adapted these and others for applications spanning from diagnostics, to gene gun engineering, to crystallography. In 2010, she co-founded SynBuild, LLC, a gene synthesis company. Dr. Sykes received her B.S. in Biology and Economics in from Duke University, her Ph.D. in Biochemistry from Duke University Medical Center, and post doc’ed in Genetics and Medicine at University of Texas, Southwestern Medical Center. She has authored more than 30 peer-reviewed publications and holds 23 patents and patent applications.
Glen Ferguson has over 20 years of experience in the Biotechnology and Molecular Diagnostics Industries, within both startup and large, multinational corporations. Glen was previously responsible for directing the business development, marketing, and strategic alliance activities for ApoCell as Vice President, Molecular Biomarkers. Prior to joining ApoCell, Glen held senior business development positions at Beckman Coulter, Cogenics/Clinical Data, and Genaissance Pharmaceuticals with a focus on developing Industry partnerships and diagnostic applications. Earlier in his career, Glen was part of the Regulatory Compliance teams at PPD and Bristol-Myers Squibb. Glen holds a BS in Biology from the College of Charleston, and an MBA from the University of North Carolina, Greensboro.
Cynthia has 20 years of experience in consumer, professional, and medical device marketing. She started her career at the world class marketing company, Procter and Gamble, where she managed various established and new products. She furthered her career creating new categories and extending brands for SC Johnson Wax in both the United States and Argentina, collaborating with several Southern Cone Countries. Importantly, Cynthia’s depth and breadth extends to OTC Drugs and Devices, with a strong understanding of FDA and physician marketing (with leadership roles in Schering Plough/Merck). As Director of Consumer and Professional Marketing for Johnson and Johnson, a $600mm Diabetes Company, she directed the largest historical initiatives: relocating diabetic devices from behind the counter(RX) to compete in traditional consumer packaged goods distribution (OTC), creating the firm’s first time DTC advertising campaign and, building a clear differentiated brand identity across a diverse product portfolio. Additionally, she lead professional marketing efforts to key physician audiences and educators. Finally, Cynthia consulted other private and public firms: developing launch, business and corporate strategies to enter the U.S. market for firms such as Nidek (laser devices), Collagen (injectable devices), Thermage (cosmetic devices), and Overseas Limited, Inc. (blood pressure monitoring devices) based in Australia.
Dr. Conley leads new investments for the firm while serving as an active Director on many of Paladin’s portfolio company Boards. Paul joined the Paladin team after more than 15 years of previous R&D and entrepreneurial experience. As founding CEO of BrightScale, he led the commercialization of a patented multi-core microprocessor technology in the HDTV market. As founding CEO of Appfluent Technology, he led the commercialization of patented in-memory distributed database technologies in the enterprise IT market. Prior to taking the entrepreneurial route, he spent nearly a decade in multidisciplinary R&D roles in the areas of high-performance computing, applied physics and biomedical engineering, including postdoctoral positions at the Los Alamos National Laboratory. Paul earned a PhD in Computational Physics and an MS in Bioengineering from UCSD, as well as an MS and BS in Mechanical and Aerospace Engineering from the University of Virginia.
Craig Asher has had a successful track record of developing software companies. Over the past ten years he has been a key team member in three successful software startups: Commerce One; Trigo Technologies; and the internal IBM startup for InfoSphere Traceability Server. He has guided major software implementations at over 50 customers in markets including retail, medical products, pharmaceuticals, and general distribution.
Following Trigo’s sale to IBM, Craig formed a new startup group within IBM to build a new product for information management software for sensor data. Craig’s role in the new venture was the product strategist, product manager, and implementation manager. In 2005 the venture signed its first customer, Glaxo Smith Kline, and Craig led the delivery to that customer in 2006. He Co-chaired the international EPCglobal EPCIS standard which was the core for the broad adoption of similar information management software, and attained ratification of the standard in 2007. Craig significantly helped sign and implement 7 additional customers until his departure from IBM to join Vital Venture Capital. In 2008 the IBM product’s customer base grew to 15 customers, annual sales were approximately $9 million and gross margin was approximately $6 million.
Craig has enjoyed co-chairing several working groups in international standards bodies. He has one issued US patent - 7,866,543. He also has extensive experience in marketing strategy, product management, product development, services delivery, business development, and technical sales for growing software companies.
Before moving into software startups, Craig was a consultant with Andersen Consulting (now Accenture) in the supply chain strategy practice, and helped drive the turnaround of a distressed packaging manufacturer. Craig did his undergraduate work at Stanford University, and completed his MBA and Masters in Industrial Engineering at Northwestern University.
Dr. Carolyn Compton is an academic pathologist who received her MD and PhD degrees from Harvard Medical School. At ASU, she is the Chief Medical and Science Officer of the National Biomarkers Development Alliance, a member of the Biodesign Institute and the Chief Medical Officer of the Complex Adaptive Systems Initiative. Her research interests are related to colon cancer, bio-‐banking and biomarkers development.
She was a professor of pathology at Harvard and Massachusetts General Hospital, Chair of Pathology at McGill University from 2000-‐2005, and Director of the Office of Biorepositories and Biospecimen Research at the National Cancer Institute until 2012. She is the past CEO and President of the Critical Path Institute. Compton is an adjunct professor of pathology at both the University of Arizona and Johns Hopkins, and research associate at Mayo Clinic.